Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Baxter
Fish and Richardson
Boehringer Ingelheim
Healthtrust

Generated: September 22, 2019

DrugPatentWatch Database Preview

Patent: 5,756,349

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,756,349
Title: Production of erythropoietin
Abstract:Disclosed are novel polypeptides possessing part or all of the primary structural conformation and one or more of the biological properties of mammalian erythropoietin (\"EPO\") which are characterized in preferred forms by being the product of procaryotic or eucaryotic host expression of an exogenous DNA sequence. Illustratively, genomic DNA, cDNA and manufactured DNA sequences coding for part or all of the sequence of amino acid residues of EPO or for analogs thereof are incorporated into autonomously replicating plasmid or viral vectors employed to transform or transfect suitable procaryotic or eucaryotic host cells such as bacteria, yeast or vertebrate cells in culture. Upon isolation from culture media or cellular lysates or fragments, products of expression of the DNA sequences display, e.g., the immunological properties and in vitro and in vivo biological activities of EPO of human or monkey species origins. Disclosed also are chemically synthesized polypeptides sharing the biochemical and immunological properties of EPO. Also disclosed are improved methods for the detection of specific single stranded polynucleotides in a heterologous cellular or viral sample prepared from, e.g., DNA present in a plasmid or viralborne cDNA or genomic DNA \"library\".
Inventor(s): Lin; Fu-Kuen (Thousand Oaks, CA)
Assignee: Amgen Inc. (Thousand Oaks, CA)
Application Number:08/468,369
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 5,756,349
Patent Claims:see list of patent claims

Details for Patent 5,756,349

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; SINGLE-USE 103234 001 1989-06-01   Try a Free Trial Amgen Inc. (Thousand Oaks, CA) 2015-05-26 RX company
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; MULTIDOSE 103234 002 1989-06-01   Try a Free Trial Amgen Inc. (Thousand Oaks, CA) 2015-05-26 RX company
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; MULTIDOSE 103234 003 1989-06-01   Try a Free Trial Amgen Inc. (Thousand Oaks, CA) 2015-05-26 RX company
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; SINGLE-USE 103234 004 1989-06-01   Try a Free Trial Amgen Inc. (Thousand Oaks, CA) 2015-05-26 RX company
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; SINGLE-USE 103234 005 1989-06-01   Try a Free Trial Amgen Inc. (Thousand Oaks, CA) 2015-05-26 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Daiichi Sankyo
US Army
Healthtrust
Mallinckrodt
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.